Abstract
Background: Previously, the only available glucagon-like peptide-1 receptor agonists (GLP-1 RA) were injectable. Approval of oral semaglutide (Rybelsu......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
